Advanced

Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course - A joint PhD student course at University College London and University of Gothenburg

Obrocki, Pawel ; Khatun, Ayesha ; Ness, Deborah ; Senkevich, Konstantin ; Hanrieder, Jörg ; Capraro, Federica ; Mattsson, Niklas LU ; Andreasson, Ulf ; Portelius, Erik and Ashton, Nicholas J. , et al. (2020) In Alzheimer's Research and Therapy 12(1).
Abstract

Until relatively recently, a diagnosis of probable Alzheimer's disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold standard for disease confirmation. This is in sharp contrast to other areas of medicine, where fluid biomarkers, such as troponin levels in myocardial infarction, form an integral part of the diagnostic and treatment criteria. There is a pressing need for such quantifiable and easily accessible tools in neurodegenerative diseases. In this paper, based on lectures given at the 2019 Biomarkers in Neurodegenerative Diseases Course, we provide an overview of a range of cerebrospinal fluid (CSF) and blood biomarkers in neurodegenerative... (More)

Until relatively recently, a diagnosis of probable Alzheimer's disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold standard for disease confirmation. This is in sharp contrast to other areas of medicine, where fluid biomarkers, such as troponin levels in myocardial infarction, form an integral part of the diagnostic and treatment criteria. There is a pressing need for such quantifiable and easily accessible tools in neurodegenerative diseases. In this paper, based on lectures given at the 2019 Biomarkers in Neurodegenerative Diseases Course, we provide an overview of a range of cerebrospinal fluid (CSF) and blood biomarkers in neurodegenerative disorders, including the 'core' AD biomarkers amyloid β (Aβ) and tau, as well as other disease-specific and general markers of neuroaxonal injury. We then highlight the main challenges in the field, and how those could be overcome with the aid of new methodological advances, such as assay automation, mass spectrometry and ultrasensitive immunoassays. As we hopefully move towards an era of disease-modifying treatments, reliable biomarkers will be essential to increase diagnostic accuracy, allow for earlier diagnosis, better participant selection and disease activity and treatment effect monitoring.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Amyloid, Biomarkers, ELISA, Mass spectrometry, Neurodegeneration, Neurofilament light, Neurogranin, Simoa, Tau, α-Synuclein
in
Alzheimer's Research and Therapy
volume
12
issue
1
article number
20
publisher
BioMed Central (BMC)
external identifiers
  • scopus:85080875678
  • pmid:32111242
ISSN
1758-9193
DOI
10.1186/s13195-020-00586-6
language
English
LU publication?
yes
id
93bd6e7d-de91-4330-9a88-ff226eb701df
date added to LUP
2020-03-18 14:25:38
date last changed
2020-03-24 07:11:33
@article{93bd6e7d-de91-4330-9a88-ff226eb701df,
  abstract     = {<p>Until relatively recently, a diagnosis of probable Alzheimer's disease (AD) and other neurodegenerative disorders was principally based on clinical presentation, with post-mortem examination remaining a gold standard for disease confirmation. This is in sharp contrast to other areas of medicine, where fluid biomarkers, such as troponin levels in myocardial infarction, form an integral part of the diagnostic and treatment criteria. There is a pressing need for such quantifiable and easily accessible tools in neurodegenerative diseases. In this paper, based on lectures given at the 2019 Biomarkers in Neurodegenerative Diseases Course, we provide an overview of a range of cerebrospinal fluid (CSF) and blood biomarkers in neurodegenerative disorders, including the 'core' AD biomarkers amyloid β (Aβ) and tau, as well as other disease-specific and general markers of neuroaxonal injury. We then highlight the main challenges in the field, and how those could be overcome with the aid of new methodological advances, such as assay automation, mass spectrometry and ultrasensitive immunoassays. As we hopefully move towards an era of disease-modifying treatments, reliable biomarkers will be essential to increase diagnostic accuracy, allow for earlier diagnosis, better participant selection and disease activity and treatment effect monitoring.</p>},
  author       = {Obrocki, Pawel and Khatun, Ayesha and Ness, Deborah and Senkevich, Konstantin and Hanrieder, Jörg and Capraro, Federica and Mattsson, Niklas and Andreasson, Ulf and Portelius, Erik and Ashton, Nicholas J. and Blennow, Kaj and Schöll, Michael and Paterson, Ross W. and Schott, Jonathan M. and Zetterberg, Henrik},
  issn         = {1758-9193},
  language     = {eng},
  month        = {02},
  number       = {1},
  publisher    = {BioMed Central (BMC)},
  series       = {Alzheimer's Research and Therapy},
  title        = {Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course - A joint PhD student course at University College London and University of Gothenburg},
  url          = {http://dx.doi.org/10.1186/s13195-020-00586-6},
  doi          = {10.1186/s13195-020-00586-6},
  volume       = {12},
  year         = {2020},
}